Schonfeld Strategic Advisors LLC Takes $15.74 Million Position in Black Diamond Therapeutics (NASDAQ:REYN)

Schonfeld Strategic Advisors LLC acquired a new stake in Black Diamond Therapeutics (NASDAQ:REYN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 452,957 shares of the company’s stock, valued at approximately $15,736,000. Schonfeld Strategic Advisors LLC owned approximately 0.22% of Black Diamond Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Global Retirement Partners LLC raised its holdings in shares of Black Diamond Therapeutics by 27.4% in the 2nd quarter. Global Retirement Partners LLC now owns 1,811 shares of the company’s stock valued at $63,000 after purchasing an additional 390 shares in the last quarter. American International Group Inc. acquired a new stake in shares of Black Diamond Therapeutics in the 1st quarter valued at $26,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Black Diamond Therapeutics in the 1st quarter valued at $29,000. Advisor Group Holdings Inc. raised its holdings in shares of Black Diamond Therapeutics by 76.0% in the 2nd quarter. Advisor Group Holdings Inc. now owns 2,423 shares of the company’s stock valued at $84,000 after purchasing an additional 1,046 shares in the last quarter. Finally, Deutsche Bank AG acquired a new stake in Black Diamond Therapeutics during the 1st quarter worth $67,000. Institutional investors and hedge funds own 26.16% of the company’s stock.

Several brokerages recently commented on REYN. BidaskClub upgraded shares of Black Diamond Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Black Diamond Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research note on Saturday, August 29th. ValuEngine lowered shares of Black Diamond Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Black Diamond Therapeutics from $37.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, July 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. Black Diamond Therapeutics currently has an average rating of “Buy” and a consensus price target of $36.60.

NASDAQ REYN traded down $0.77 during trading on Wednesday, reaching $31.61. The company’s stock had a trading volume of 494,337 shares, compared to its average volume of 729,074. The company has a debt-to-equity ratio of 1.63, a quick ratio of 1.82 and a current ratio of 2.81. The firm has a market cap of $6.63 billion and a price-to-earnings ratio of 21.80. Black Diamond Therapeutics has a twelve month low of $21.61 and a twelve month high of $36.00. The business’s fifty day moving average price is $32.94 and its 200-day moving average price is $32.04.

Black Diamond Therapeutics (NASDAQ:REYN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. The business had revenue of $798.00 million during the quarter, compared to analyst estimates of $853.11 million. The business’s revenue was up 6.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Black Diamond Therapeutics will post 1.94 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Sunday, August 16th were issued a $0.22 dividend. This is an increase from Black Diamond Therapeutics’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend was Thursday, August 13th. This represents a $0.88 annualized dividend and a dividend yield of 2.78%. Black Diamond Therapeutics’s payout ratio is presently 60.69%.

In other news, Director Richard A. Noll bought 15,000 shares of the stock in a transaction dated Monday, August 17th. The shares were acquired at an average price of $33.41 per share, with a total value of $501,150.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

About Black Diamond Therapeutics

Reynolds Consumer Products Inc, a consumer products company, produces and sells products across cooking, waste and storage, and tableware. It operates through four segments: Reynolds Cooking & Baking, Hefty Waste & Storage, Hefty Tableware, and Presto Products. The Reynolds Cooking & Baking segment produce foil, parchment paper, and disposable aluminum pans, as well as cooker liners.

Featured Story: What sectors are represented in the Nikkei Index?

Institutional Ownership by Quarter for Black Diamond Therapeutics (NASDAQ:REYN)

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.